{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-023285","form_type":"8-K","ticker":"ANIX","cik":"0000715446","company_name":"Anixa Biosciences Inc","filed_at":"2022-08-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.980080+00:00","generated_at":"2026-06-23T23:16:17.095489+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Anixa Biosciences doses first patient in Phase 1 CAR-T trial for ovarian cancer","bullets":["First patient dosed in Phase 1 trial of novel CER-T therapy for ovarian cancer at Moffitt Cancer Center.","Dose-escalation study to evaluate safety, maximum tolerated dose, and preliminary efficacy.","Trial targets follicle stimulating hormone receptor (FSHR) on ovarian cells.","Up to 48 patients may be enrolled in the study.","CER-T approach differs from traditional CAR-T by targeting an endocrine receptor."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-023285","json":"https://secwatch.observer/filing/0001493152-22-023285.json","markdown":"https://secwatch.observer/filing/0001493152-22-023285.md","text":"https://secwatch.observer/filing/0001493152-22-023285.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/715446/000149315222023285/0001493152-22-023285-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/715446/000149315222023285/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T23:16:17.095489+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}